Eisai Asks Court To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai says DEA’s scheduling delay – 10 months after FDA approval and seven months after HHS submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.